Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the Meantime, Some Challenges and Recommendations

被引:31
作者
Martin, Seth S. [1 ]
Metkus, Thomas S. [1 ]
Horne, Aaron [1 ]
Blaha, Michael J. [1 ]
Hasan, Rani [1 ]
Campbell, Catherine Y. [1 ]
Yousuf, Omair [1 ]
Joshi, Parag [1 ]
Kaul, Sanjay [2 ]
Miller, Michael [3 ]
Michos, Erin D. [1 ]
Jones, Steven R. [1 ]
Gluckman, Ty J. [4 ]
Cannon, Christopher P. [5 ]
Sperling, Laurence S. [6 ]
Blumenthal, Roger S. [1 ]
机构
[1] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA
[2] Cedars Sinai Med Ctr, Div Cardiovasc, Los Angeles, CA 90048 USA
[3] Univ Maryland, Sch Med, Div Cardiovasc, Baltimore, MD 21201 USA
[4] Providence Heart & Vasc Inst, Portland, OR USA
[5] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA
[6] Emory Univ, Sch Med, Div Cardiovasc, Atlanta, GA USA
关键词
LOW-DENSITY-LIPOPROTEIN; ASSOCIATION TASK-FORCE; CARDIOVASCULAR-DISEASE; LDL CHOLESTEROL; APOLIPOPROTEIN-B; FOCUSED UPDATE; RISK; MANAGEMENT; ATHEROSCLEROSIS; METAANALYSIS;
D O I
10.1016/j.amjcard.2012.03.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The National Cholesterol Education Program Adult Treatment Panel (ATP) has provided education and guidance for decades on the management of hypercholesterolemia. Its third report (ATP III) was published 10 years ago, with a white paper update in 2004. There is a need for translation of more recent evidence into a revised guideline. To help address the significant challenges facing the ATP IV writing group, this statement aims to provide balanced recommendations that build on ATP III. The authors aim for simplicity to increase the likelihood of implementation in clinical practice. To move from ATP III to ATP IV, the authors recommend the following: (1) assess risk more accurately, (2) simplify the starting algorithm, (3) prioritize statin therapy, (4) relax the follow-up interval for repeat lipid testing, (5) designate <70 mg/di as an "ideal" low-density lipoprotein cholesterol target, (6) endorse targets beyond low-density lipoprotein cholesterol, (7) refine therapeutic target levels to the equivalent population percentile, (8) remove misleading descriptors such as "borderline high," and (9) make lifestyle messages simpler. In conclusion, the solutions offered in this statement represent ways to translate the totality of published reports into enhanced hyperlipidemia guidelines to better combat the devastating impact of hyperlipidemia on cardiovascular health. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:307-313)
引用
收藏
页码:307 / 313
页数:7
相关论文
共 30 条
[21]   Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction The American Heart Association's Strategic Impact Goal Through 2020 and Beyond [J].
Lloyd-Jones, Donald M. ;
Hong, Yuling ;
Labarthe, Darwin ;
Mozaffarian, Dariush ;
Appel, Lawrence J. ;
Van Horn, Linda ;
Greenlund, Kurt ;
Daniels, Stephen ;
Nichol, Graham ;
Tomaselli, Gordon F. ;
Arnett, Donna K. ;
Fonarow, Gregg C. ;
Ho, P. Michael ;
Lauer, Michael S. ;
Masoudi, Frederick A. ;
Robertson, Rose Marie ;
Roger, Veronique ;
Schwamm, Lee H. ;
Sorlie, Paul ;
Yancy, Clyde W. ;
Rosamond, Wayne D. .
CIRCULATION, 2010, 121 (04) :586-613
[22]   Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference [J].
Mancini, G. B. John ;
Baker, Steven ;
Bergeron, Jean ;
Fitchett, David ;
Frohlich, Jiri ;
Genest, Jacques ;
Gupta, Milan ;
Hegele, Robert A. ;
Ng, Dominic ;
Pope, Janet .
CANADIAN JOURNAL OF CARDIOLOGY, 2011, 27 (05) :635-662
[23]  
Mihaylova B, 2006, BMJ-BRIT MED J, V333, P1
[24]   Optimal low-density lipoprotein is 50 to 70 mg/dl - Lower is better and physiologically normal [J].
O'Keefe, JH ;
Cordain, L ;
Harris, WH ;
Moe, RM ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (11) :2142-2146
[25]   Diets and cardiovascular disease - An evidence-based assessment [J].
Parikh, P ;
McDaniel, MC ;
Ashen, D ;
Miller, JI ;
Sorrentino, M ;
Chan, V ;
Blumenthal, RS ;
Sperling, LS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (09) :1379-1387
[26]   Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification Do the Math [J].
Ramjee, Vimal ;
Sperling, Laurence S. ;
Jacobson, Terry A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (05) :457-463
[27]   Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials [J].
Sattar, Naveed ;
Preiss, David ;
Murray, Heather M. ;
Welsh, Paul ;
Buckley, Brendan M. ;
de Craen, Anton J. M. ;
Seshasai, Sreenivasa Rao Kondapally ;
McMurray, John J. ;
Freeman, Dilys J. ;
Jukema, J. Wouter ;
Macfarlane, Peter W. ;
Packard, Chris J. ;
Stott, David J. ;
Westendorp, Rudi G. ;
Shepherd, James ;
Davis, Barry R. ;
Pressel, Sara L. ;
Marchioli, Roberto ;
Marfisi, Rosa Maria ;
Maggioni, Aldo P. ;
Tavazzi, Luigi ;
Tognoni, Gianni ;
Kjekshus, John ;
Pedersen, Terje R. ;
Cook, Thomas J. ;
Gotto, Antonio M. ;
Clearfield, Michael B. ;
Downs, John R. ;
Nakamura, Haruo ;
Ohashi, Yasuo ;
Mizuno, Kyoichi ;
Ray, Kausik K. ;
Ford, Ian .
LANCET, 2010, 375 (9716) :735-742
[28]   The Friedewald formula underestimates LDL cholesterol at low concentrations [J].
Scharnagl, H ;
Nauck, M ;
Wieland, H ;
März, W .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (05) :426-431
[29]   A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk [J].
Sniderman, Allan D. ;
Williams, Ken ;
Contois, John H. ;
Monroe, Howard M. ;
McQueen, Matthew J. ;
de Graaf, Jacqueline ;
Furberg, Curt D. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (03) :337-U144
[30]   Subendothelial lipoprotein retention as the initiating process in atherosclerosis -: Update and therapeutic implications [J].
Tabas, Ira ;
Williams, Kevin Jon ;
Boren, Jan .
CIRCULATION, 2007, 116 (16) :1832-1844